AIM
NRIX icon

ARK Investment Management’s Nurix Therapeutics NRIX Stock Holding History

ARK Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.5M Buy
1,793,196
+72,061
+4% +$1.23M 0.28% 65
2026
Q1 		$26.7M Buy
1,721,135
+118,596
+7% +$1.97M 0.21% 72
2025
Q4 		$30.4M Buy
1,602,539
+92,135
+6% +$1.32M 0.2% 74
2025
Q3 		$14M Sell
1,510,404
-64,628
-4% -$671K 0.08% 101
2025
Q2 		$17.9M Sell
1,575,032
-15,878
-1% -$172K 0.13% 76
2025
Q1 		$18.9M Buy
1,590,910
+60,617
+4% +$1.01M 0.19% 68
2024
Q4 		$28.8M Sell
1,530,293
-686,072
-31% -$15.7M 0.24% 57
2024
Q3 		$49.8M Sell
2,216,365
-106,967
-5% -$2.42M 0.46% 43
2024
Q2 		$48.5M Sell
2,323,332
-312,006
-12% -$4.86M 0.43% 38
2024
Q1 		$38.7M Sell
2,635,338
-559,661
-18% -$6.02M 0.27% 56
2023
Q4 		$33M Buy
3,194,999
+601,952
+23% +$4.13M 0.2% 63
2023
Q3 		$20.4M Buy
2,593,047
+331,976
+15% +$3.03M 0.16% 76
2023
Q2 		$22.6M Buy
2,261,071
+21,212
+0.9% +$216K 0.15% 80
2023
Q1 		$19.9M Buy
2,239,859
+251,605
+13% +$2.62M 0.14% 73
2022
Q4 		$21.8M Buy
1,988,254
+701,732
+55% +$8.46M 0.19% 67
2022
Q3 		$16.8M Buy
1,286,522
+507,797
+65% +$8.04M 0.12% 90
2022
Q2 		$7.86M Buy
778,725
+386,734
+99% +$4.38M 0.05% 126
2022
Q1 		$5.49M Buy
391,991
+348,044
+792% +$6.18M 0.02% 152
2021
Q4 		$1.27M Buy
+43,947
New +$1.33M ﹤0.01% 252

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ARK Investment Management's NRIX Position: Q2 2026 in Review

ARK Investment Management increased its Nurix Therapeutics (NRIX) stake by 4.2% in Q2 2026, buying an estimated $1.23M and bringing the position to 1,793,196 shares worth $43.5M. The position accounts for 0.28% of the portfolio, ranked #65.

ARK Investment Management first reported a position in NRIX in Q4 2021 and has held it in 19 quarters since. The position peaked at $49.8M in Q3 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • ARK Investment Management held 1,793,196 shares of Nurix Therapeutics worth $43.5M as of Q2 2026.
  • ARK Investment Management bought 72,061 Nurix Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Nurix Therapeutics made up 0.28% of ARK Investment Management's portfolio in Q2 2026, its #65 holding.
  • ARK Investment Management first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • ARK Investment Management's Nurix Therapeutics position peaked at $49.8M in Q3 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.